{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-21-017524","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.491301+00:00","generated_at":"2026-06-28T10:27:35.841044+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex","bullets":["Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.","Non-GAAP operating margin improvement targeted towards ~22.5% by 2024.","Staffing levels increased ahead of plan; compensation expected to be headwind in 2022.","Capital expenditure guided at ~9% of total revenue in 2022, mainly for Safety Assessment capacity.","Outlook presented at Credit Suisse 30th Annual Healthcare Conference on Nov 9, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-21-017524","json":"https://secwatch.observer/filing/0000950103-21-017524.json","markdown":"https://secwatch.observer/filing/0000950103-21-017524.md","text":"https://secwatch.observer/filing/0000950103-21-017524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/0000950103-21-017524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/dp161446_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:27:35.841044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}